• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Hawkins, Inc. Reports Fourth Quarter and Fiscal Year 2024 Results

    5/15/24 4:10:16 PM ET
    $HWKN
    Specialty Chemicals
    Consumer Discretionary
    Get the next $HWKN alert in real time by email

    ROSEVILLE, Minn., May 15, 2024 (GLOBE NEWSWIRE) -- Hawkins, Inc. (NASDAQ:HWKN), a leading specialty chemical and ingredients company, today announced fourth quarter and full-year results for its fiscal year ended March 31, 2024.

    Fourth Quarter Fiscal Year 2024 Highlights:

    • Fourth quarter sales of $223.0 million, down 2% compared to the same quarter in the prior year, with Water Treatment segment sales growth of 21% over the same quarter in the prior year.
    • Gross profit of $45.5 million, a 27% increase over the same quarter in the prior year, contributing to a 9% increase in operating income in the quarter.
    • Record fourth quarter diluted earnings per share (EPS) of $0.66, which was 20% higher than the same period of the prior year.
    • Adjusted Earnings Before Interest, Taxes, Depreciation, and Amortization (adjusted EBITDA), a non-GAAP measure, of $31.0 million, a 15% increase over the same period of the prior year.
    • Record fourth quarter operating cash flow of $41.9 million allowed us to pay down $21 million in debt in the quarter.

    Full-Year Fiscal Year 2024 Highlights:

    • Full year sales of $919.2 million, down 2% compared to the prior fiscal year, with Water Treatment up 19% over the prior year.  
    • Record gross profit of $193.6 million, a 17% increase over the prior year, contributing to an 18% year-over-year increase in operating income.
    • Record diluted EPS of $3.59, which was $0.73, or 26%, higher than fiscal 2023.
    • Record adjusted EBITDA, a non-GAAP measure, of $143.0 million, an increase of 20% over fiscal 2023.
    • Record operating cash flow of $159.5 million, which was more than double that of fiscal 2023.
    • Completed four acquisitions in our Water Treatment segment while paying down our debt, ending the year with net debt of $91.8 million and a leverage ratio of 0.66x EBITDA.
    • Paid cash dividends of $0.63 per share for the year, an increase of 11% over the prior year. This marks the 39th consecutive year of paying a dividend.

    Executive Commentary – Patrick H. Hawkins, Chief Executive Officer and President:

    "We had an excellent fiscal 2024. This included record operating cash flow, and, for the sixth year in a row, record operating income, net income, diluted EPS, and adjusted EBITDA. This performance provided the necessary capital for us to invest in the business and complete four acquisitions within the year that were fully funded by our cash flow. The cash flow also allowed us to continue to deliver shareholder value with dividends and share repurchases while paying down our debt resulting in a leverage ratio below 1x EBITDA. Cumulatively, all of these factors have driven our stock appreciation. This performance is the result of the hard work by our many employees, our innovative approach to business, as well as our outstanding relationships with our customers and suppliers, which we never take for granted."

    Mr. Hawkins, continued, "Our continued focus on executing our growth strategy resulted in the completion of four acquisitions in our Water Treatment segment in fiscal 2024, adding eight facilities and over 100 employees. The Water Treatment segment's operating income grew 69% to $53 million in the year, on revenue growth of 19%. Sales in our Industrial segment decreased 13% driven primarily by lower overall volumes as well as the divestiture of our consumer bleach packaging business, which we sold at the end of fiscal 2023. However, because of our diverse product offerings and disciplined margin management, even with that sales decline, our gross profit in the Industrial segment was relatively flat year over year. Our Health and Nutrition segment sales decreased from the prior year, and, as anticipated, we did see improved year-over-year sales performance throughout the year, as customers worked through overstocking situations. In the fourth quarter, revenue for the Health and Nutrition segment grew slightly compared to declines in the previous quarters."

    Mr. Hawkins continued, "We are extremely proud of what we accomplished over the past year, and over the past several years. As we look to fiscal 2025, we expect to see continued top and bottom-line growth, with our top line approaching $1 billion in revenue and Water Treatment becoming our largest reporting segment. We are cautiously optimistic about our Industrial segment, but we believe economic and competitive pressures will continue to weigh on many of our customers and impact demand. In Health and Nutrition, we expect the improved performance we saw in the latter half of fiscal 2024 to continue into fiscal 2025, and expect results to be higher than fiscal 2024. With the diversity of our businesses and the overall strength of our Company, we believe we will continue to generate strong operating cash flow that will allow us to fund future investments for growth while continuing to pay down debt during fiscal year 2025."

    Fourth Quarter and Fiscal Year Financial Highlights:

    NET INCOME

    For the fourth quarter of fiscal 2024, the Company reported net income of $13.8 million, or $0.66 per diluted share, compared to net income for the fourth quarter of fiscal 2023 of $11.6 million, or $0.55 per diluted share.

    For the full year, the Company reported record net income of $75.4 million, or $3.59 per diluted share, compared to net income for fiscal 2023 of $60.0 million, or $2.86 per diluted share.

    REVENUE

    For the fourth quarter of fiscal 2024, sales were $223.0 million, a decrease of $5.1 million, or 2%, from sales of $228.1 million a year ago. Increased sales in our Water Treatment segment were more than offset by decreased sales in our Industrial segment. Industrial segment sales decreased $20.6 million, or 18%, to $97.1 million for the fourth quarter, as compared to $117.7 million for the same period a year ago. The sale of our consumer bleach packaging business at the end of fiscal 2023 resulted in $3.0 million lower sales in the current quarter. In addition, sales declined due to lower selling prices on certain products driven by lower raw material costs and competitive pricing as well as lower volumes. Water Treatment segment sales increased $15.3 million, or 21%, to $86.7 million for the fourth quarter, as compared to $71.4 million for the same period a year ago. Sales increased primarily as a result of $14.1 million of added sales from acquired businesses. Health and Nutrition segment sales increased $0.2 million to $39.3 million for the fourth quarter, as compared to $39.1 million for the same period a year ago. Increased sales of our distributed products were virtually offset by a decrease in sales of our manufactured products.

    For fiscal 2024, Industrial segment sales were $409.5 million, a decrease of 13% from fiscal 2023 sales of $470.8 million. Water Treatment segment sales were $363.3 million for the year, an increase of 19% over last year's sales of $304.9 million; of the $58.4 million increase, $23.9 million was from our acquired businesses in fiscal 2024. Sales for our Health and Nutrition segment were $146.4 million in fiscal 2024, a decrease of 8%, from fiscal 2023 sales of $159.4 million.

    GROSS PROFIT

    Company-wide gross profit for fiscal 2024 increased $28.5 million, or 17%, to $193.6 million, or 21% of sales, from $165.1 million, or 18% of sales, for fiscal 2023. During fiscal 2024, the LIFO reserve decreased, and gross profits increased, by $15.4 million, primarily due to decreased raw material costs. During fiscal 2023, the LIFO reserve increased, and gross profits decreased, by $18.5 million, primarily due to rising raw material costs. Included as a reduction to gross profit in the current year was a $7.7 million charge to operating expense for an environmental liability related to perchlorinated biphenyls (PCBs) discovered in the soil at our Rosemount, MN facility, with such expense reflected in our Industrial segment. While the source of the PCBs is unknown, we have never brought PCBs onto the property or used PCBs on the site.

    Gross profit for the Industrial segment decreased $0.6 million, or 1%, to $67.5 million, or 16% of sales, for fiscal 2024, from $68.1 million, or 14% of sales, for fiscal 2023. During fiscal 2024 the LIFO reserve decreased, and gross profits increased, by $12.1 million, primarily due to decreased raw material costs. During fiscal 2023, the LIFO reserve increased, and gross profits decreased, by $12.3 million, primarily due to rising raw material costs.

    Gross profit for the Water Treatment segment increased $31.3 million, or 47%, to $98.5 million, or 27% of sales, for fiscal 2024, from $67.2 million, or 22% of sales, for fiscal 2023. During fiscal 2024, the LIFO reserve decreased, and gross profits increased, by $3.3 million, primarily due to decreased raw material costs. During fiscal 2023, the LIFO reserve increased, and gross profit decreased, by $6.2 million, primarily due to rising raw material costs. Gross profit increased as a result of improved per-unit margins on many of our products as well as increased sales, including the added sales from acquired businesses.

    Gross profit for the Health and Nutrition segment decreased $2.2 million, or 7%, to $27.6 million, or 19% of sales, for fiscal 2024, from $29.8 million, or 19% of sales, for fiscal 2023. Gross profit decreased due to lower sales.

    SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

    Selling, general and administrative ("SG&A") expenses increased $12.6 million, or 16%, to $89.6 million, or 10% of sales, for fiscal 2024 from $77.0 million, or 8% of sales, for fiscal 2023. Included in SG&A expenses for the prior year was a gain of approximately $3.0 million related to the sale of certain assets related to our consumer bleach packaging business. In addition, a year-over-year increase in compensation expense of $1.4 million related to our non-qualified deferred compensation plan reduced SG&A expenses, with the offset in Other Expense. Additionally, expenses increased due to the added costs from the acquired businesses in our Water Treatment segment of $5.8 million, including $1.8 million of amortization of intangibles, as well as increased variable expenses, most notably variable pay.

    ADJUSTED EBITDA

    Adjusted EBITDA, a non-GAAP financial measure, is an important performance indicator and a key compliance measure under the terms of our credit agreement. An explanation of the computation of adjusted EBITDA is presented below. Adjusted EBITDA for the three months ended March 31, 2024, was $31.0 million, an increase of $4.0 million, or 15%, from adjusted EBITDA of $27.0 million for the same period in the prior year. Full-year adjusted EBITDA was $143.0 million, an increase of $23.9 million, or 20%, from adjusted EBITDA of $119.1 million for fiscal 2023. The increase was due to the impact of improved gross profits discussed above.

    INCOME TAXES

    Our effective tax rate was approximately 26% for fiscal 2024 and 27% for fiscal 2023. The effective tax rate is impacted by projected levels of annual taxable income, permanent items, and state taxes. The current year decrease in the effective tax rate was primarily driven by favorable tax provision adjustments recorded.

    BALANCE SHEET

    At the end of fiscal 2024, our working capital was $42 million lower than the end of fiscal 2023 due to favorable cash collections on accounts receivable and disciplined management of our inventory levels. For the year, our record operating cash flow of $159 million was used to fund $83 million in acquisition spending for the acquisitions of EcoTech, Water Solutions, Miami Products and Industrial Research, capital spending of $40 million, dividend payments of $13 million, stock repurchases of $11 million, and net debt repayments of $13 million. Our total debt outstanding at the end of fiscal 2024 was $99 million and our leverage ratio was 0.66 times our trailing twelve-month proforma adjusted EBITDA, as compared to 0.96x at the end of fiscal 2023.

    About Hawkins, Inc.

    Hawkins, Inc. was founded in 1938 and is a leading specialty chemical and ingredients company that formulates, distributes, blends and manufactures products for its Industrial, Water Treatment, and Health & Nutrition customers. Headquartered in Roseville, Minnesota, the Company has 59 facilities in 26 states and creates value for its customers through superb customer service and support, quality products and personalized applications. Hawkins, Inc. generated $919 million of revenue in fiscal 2024 and has approximately 950 employees. For more information, including registering to receive email alerts, please visit www.hawkinsinc.com/investors.

    Reconciliation of Non-GAAP Financial Measures

    We report our consolidated financial results in accordance with U.S. generally accepted accounting principles (GAAP). To assist investors in understanding our financial performance between periods, we have provided certain financial measures not computed according to GAAP, including adjusted EBITDA. This non-GAAP financial measure is not meant to be considered in isolation or as a substitute for comparable GAAP measures. The method we use to produce non-GAAP results is not computed according to GAAP and may differ from the methods used by other companies.

    Management uses this non-GAAP financial measure internally to understand, manage and evaluate our business and to make operating decisions. Management believes that this non-GAAP financial measure reflects an additional way of viewing aspects of our operations that, when viewed with our GAAP results, provides a more complete understanding of the factors and trends affecting our financial condition and results of operations.

    We define adjusted EBITDA as GAAP net income adjusted for the impact of the following: net interest expense resulting from our net borrowing position; income tax expense; non-cash expenses including amortization of intangibles, depreciation, and charges for the employee stock purchase plan and restricted stock grants; and non-recurring items of income or expense, if applicable.

    Adjusted EBITDAThree Months Ended Fiscal Year Ended
    (In thousands)March 31, 2024 April 2, 2023 March 31, 2024 April 2, 2023
    Net income (GAAP)$13,832 $11,613 $75,363 $60,041
    Interest expense 1,249  1,376  4,282  5,234
    Income tax expense 5,493  5,904  25,782  22,541
    Amortization of intangibles 2,753  1,677  8,539  6,924
    Depreciation expense 6,201  5,390  23,264  20,516
    Non-cash compensation expense 1,374  1,061  4,880  3,825
    Non-recurring acquisition expense 85  —  917  —
    Adjusted EBITDA$30,987 $27,021 $143,027 $119,081
     

    HAWKINS, INC.

    CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)

    (In thousands, except share and per-share data)

      Three Months Ended Fiscal Year Ended
      March 31, 2024 April 2, 2023 March 31, 2024 April 2, 2023
      (unaudited)    
    Sales $223,020  $228,145  $919,162  $935,098 
    Cost of sales  (177,509)  (192,420)  (725,526)  (769,979)
    Gross profit  45,511   35,725   193,636   165,119 
    Selling, general and administrative expenses  (25,427)  (17,242)  (89,600)  (76,969)
    Operating income  20,084   18,483   104,036   88,150 
    Interest expense, net  (1,249)  (1,376)  (4,282)  (5,234)
    Other income (expense)  490   410   1,391   (334)
    Income before income taxes  19,325   17,517   101,145   82,582 
    Income tax expense  (5,493)  (5,904)  (25,782)  (22,541)
    Net income $13,832  $11,613  $75,363  $60,041 
             
    Weighted average number of shares outstanding-basic  20,790,260   20,850,454   20,864,348   20,848,077 
    Weighted average number of shares outstanding-diluted  20,929,056   21,024,649   21,014,326   21,014,905 
             
    Basic earnings per share $0.67  $0.56  $3.61  $2.88 
    Diluted earnings per share $0.66  $0.55  $3.59  $2.86 
                     

    HAWKINS, INC.

    CONSOLIDATED BALANCE SHEETS (UNAUDITED)

    (In thousands, except share and per-share data)

      March 31, 2024 April 2, 2023
    ASSETS    
    CURRENT ASSETS:    
    Cash and cash equivalents $7,153 $7,566
    Trade accounts receivables, net  114,477  129,252
    Inventories  74,600  88,777
    Prepaid expenses and other current assets  6,596  6,449
    Total current assets  202,826  232,044
    PROPERTY, PLANT, AND EQUIPMENT:    
    Land  17,916  16,344
    Buildings and improvements  147,701  134,901
    Machinery and equipment  141,262  125,970
    Transportation equipment  67,868  56,328
    Office furniture and equipment  11,901  11,210
       386,648  344,753
    Less accumulated depreciation  177,774  158,950
    Net property, plant, and equipment  208,874  185,803
    OTHER ASSETS:    
    Right-of-use assets  11,713  10,199
    Goodwill  103,399  77,401
    Intangible assets, net  116,626  73,060
    Deferred compensation plan asset  9,584  7,367
    Other  4,912  4,661
    Total other assets  246,234  172,688
    Total assets $657,934 $590,535
    LIABILITIES AND SHAREHOLDERS' EQUITY    
    CURRENT LIABILITIES:    
    Accounts payable — trade $56,387 $53,705
    Accrued payroll and employee benefits  19,532  17,279
    Current portion of long-term debt  9,913  9,913
    Income tax payable  1,943  3,329
    Environmental remediation  7,700  —
    Other current liabilities  7,832  6,645
    Total current liabilities  103,307  90,871
    LONG-TERM DEBT  88,818  101,731
    LONG-TERM LEASE LIABILITY  9,530  8,687
    PENSION WITHDRAWAL LIABILITY  3,538  3,912
    DEFERRED COMPENSATION LIABILITY  11,764  9,343
    DEFERRED INCOME TAXES  22,406  23,800
    EARNOUT LIABILITY  11,235  —
    OTHER LONG-TERM LIABILITIES  1,310  2,175
    Total liabilities  251,908  240,519
    COMMITMENTS AND CONTINGENCIES    
    SHAREHOLDERS' EQUITY:    
    Common shares; authorized: 60,000,000 shares of $0.01 par value; 20,790,261 and 20,850,454 shares issued and outstanding for 2024 and 2023, respectively  208  209
    Additional paid-in capital  38,154  44,443
    Retained earnings  364,549  302,424
    Accumulated other comprehensive income  3,115  2,940
    Total shareholders' equity  406,026  350,016
    Total liabilities and shareholders' equity $657,934 $590,535
     

    HAWKINS, INC.

    CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

    (In thousands)

       Fiscal Year Ended
      March 31, 2024 April 2, 2023
    CASH FLOWS FROM OPERATING ACTIVITIES:    
    Net income $75,363  $60,041 
    Reconciliation to cash flows:    
    Depreciation and amortization  31,803   27,440 
    Change in fair value of earnout liability  571   — 
    Operating leases  2,708   1,971 
    (Gain) loss on deferred compensation assets  (1,391)  334 
    Deferred income taxes  (1,459)  (232)
    Stock compensation expense  4,880   3,825 
    Gain from asset disposals  (85)  (2,950)
    Other  87   87 
    Changes in operating accounts (using) providing cash, net of acquisitions:    
    Trade receivables  21,399   (6,389)
    Inventories  19,921   4,717 
    Accounts payable  (828)  (11,596)
    Accrued liabilities  10,708   (737)
    Lease liabilities  (2,676)  (1,958)
    Income taxes  (1,390)  3,290 
    Other  (112)  (443)
    Net cash provided by operating activities  159,499   77,400 
    CASH FLOWS FROM INVESTING ACTIVITIES:    
    Additions to property, plant, and equipment  (40,151)  (48,321)
    Acquisitions  (83,455)  — 
    Proceeds from asset disposals  1,102   7,091 
    Net cash used in investing activities  (122,504)  (41,230)
    CASH FLOWS FROM FINANCING ACTIVITIES:    
    Cash dividends paid  (13,238)  (12,001)
    New shares issued  2,242   2,008 
    Shares surrendered for payroll taxes  (2,140)  (1,550)
    Shares repurchased  (11,272)  (6,557)
    Payments on senior secured revolving loan  (98,000)  (59,000)
    Borrowings on senior secured revolving loan  85,000   45,000 
    Net cash used in financing activities  (37,408)  (32,100)
    NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS  (413)  4,070 
    CASH AND CASH EQUIVALENTS - beginning of year  7,566   3,496 
    CASH AND CASH EQUIVALENTS - end of year $7,153  $7,566 
    SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION-    
    Cash paid during the year for income taxes $28,631  $19,485 
    Cash paid for interest  4,654   4,759 
    Noncash investing activities - Capital expenditures in accounts payable  2,697   2,340 
             

    HAWKINS, INC.

    REPORTABLE SEGMENTS (UNAUDITED)

    (In thousands)

      Industrial Water

    Treatment
     Health and

    Nutrition
     Total
             
    Fiscal Year Ended March 31, 2024:        
    Sales $409,465 $363,289 $146,408 $919,162
    Gross profit  67,545  98,498  27,593  193,636
    Selling, general, and administrative expenses  28,316  45,286  15,998  89,600
    Operating income  39,229  53,212  11,595  104,036
             
    Fiscal Year Ended April 2, 2023:        
    Sales $470,760 $304,925 $159,413 $935,098
    Gross profit  68,115  67,208  29,796  165,119
    Selling, general, and administrative expenses  25,703  35,734  15,532  76,969
    Operating income (loss)  42,412  31,474  14,264  88,150
                 

    Forward-Looking Statements. Various remarks in this press release constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include those relating to expectations for results in our business segments and our ability to generate cash flow and pay down debt. These statements are not historical facts, but rather are based on our current expectations, estimates and projections, and our beliefs and assumptions. Forward-looking statements may be identified by terms, including "anticipate," "believe," "can," "could," "expect," "intend," "may," "predict," "should," or "will" or the negative of these terms or other comparable terms. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, some of which are beyond our control and are difficult to predict. Actual results may vary materially from those contained in forward looking statements based on a number of factors, including, but not limited to, changes in regulation, changes in the labor markets, changes in competition and price pressures, changes in demand and customer requirements or processes for our products, availability of product and disruptions to supplies, interruptions in production resulting from hazards, transportation limitations or other extraordinary events outside our control that may negatively impact our business or the supply chains in which we participate, changes in imported products and tariff levels, the availability of products and the prices at which they are available, the acceptance of new products by our customers and the timing of any such acceptance, changes in pricing of our products and our ability to pass any changes on to our customers, changes in product supplies and the terms of our credit agreement. Additional information concerning potential factors that could affect future financial results is included in our Annual Report on Form 10-K for the fiscal year ended April 2, 2023, as updated from time to time in amendments and subsequent reports filed with the SEC. Investors should take such risks into account when making investment decisions. Shareholders and other readers are cautioned not to place undue reliance on forward-looking statements, which reflect our management's view only as of the date hereof. We do not undertake any obligation to update any forward-looking statements.

    Contacts: Jeffrey P. Oldenkamp
      Executive Vice President and Chief Financial Officer
      612/331-6910
      [email protected] 
       

     



    Primary Logo

    Get the next $HWKN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HWKN

    DatePrice TargetRatingAnalyst
    7/24/2025Mkt Perform
    Raymond James
    4/14/2025$160.00Neutral → Buy
    BWS Financial
    4/1/2025$125.00Market Outperform
    CJS Securities
    10/16/2024Buy → Neutral
    BWS Financial
    8/7/2023$62.00Neutral → Buy
    BWS Financial
    2/3/2022$44.00 → $52.00Buy
    BWS Financial
    More analyst ratings

    $HWKN
    SEC Filings

    View All

    SEC Form 10-Q filed by Hawkins Inc.

    10-Q - HAWKINS INC (0000046250) (Filer)

    1/28/26 4:14:20 PM ET
    $HWKN
    Specialty Chemicals
    Consumer Discretionary

    Hawkins Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - HAWKINS INC (0000046250) (Filer)

    1/28/26 4:12:57 PM ET
    $HWKN
    Specialty Chemicals
    Consumer Discretionary

    Hawkins Inc. filed SEC Form 8-K: Leadership Update

    8-K - HAWKINS INC (0000046250) (Filer)

    12/19/25 8:18:42 AM ET
    $HWKN
    Specialty Chemicals
    Consumer Discretionary

    $HWKN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hawkins, Inc. to Participate in Raymond James & Associates' Annual Institutional Investor Conference

    ROSEVILLE, Minn., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Hawkins, Inc. (NASDAQ:HWKN), a leading water treatment and specialty ingredients company, today announced that Patrick Hawkins, Chief Executive Officer, and Jeff Oldenkamp, Chief Financial Officer, will participate in Raymond James & Associates' 47th Annual Institutional Investors Conference on March 3rd and 4th, 2026 in Orlando, Florida. The Raymond James Institutional Investors Conference provides an annual forum for portfolio managers and generalists to learn about sound investment opportunities from a wide range of companies across several industries covered by Raymond James. The 2025 conference attracted approximately 2,000 in-perso

    2/18/26 8:30:00 AM ET
    $HWKN
    Specialty Chemicals
    Consumer Discretionary

    Hawkins, Inc. Announces Milestone for its WaterSurplus NanoStack™ Membranes

    ROSEVILLE, Minn., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Hawkins, Inc. (NASDAQ:HWKN), a leading water treatment and specialty ingredients company, today announced the successful completion of a multi-year pilot test featuring WaterSurplus' patented NanoStack™ coated membranes at the Orange County Water District's (OCWD) Groundwater Replenishment System (GWRS). WaterSurplus is a wholly owned subsidiary of Hawkins, Inc. and is located in Loves Park, IL.  Based on the successful pilot, OCWD will install 1,050 NanoStack™ coated membranes at GWRS, the world's largest advanced water purification system for potable water reuse. This quantity represents one full reverse osmosis train, treating approx

    2/2/26 8:30:00 AM ET
    $HWKN
    Specialty Chemicals
    Consumer Discretionary

    Hawkins, Inc. Reports Third Quarter Fiscal 2026 Results

    ROSEVILLE, Minn., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Hawkins, Inc. (NASDAQ:HWKN) today announced results for the three and nine months ended December 28, 2025, its third quarter of fiscal 2026. Third Quarter Fiscal Year 2026 Highlights: Record third quarter results for revenue, gross profit, operating income, and adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("adjusted EBITDA"), a non-GAAP measure.Revenue growth of 8% over the same period of the prior year, including Water Treatment segment growth of 21% and Industrial Solutions segment growth of 10%.Gross profit increased 5% over the same period of the prior year.Diluted earnings per share ("EPS") of $0.69 decre

    1/28/26 4:10:00 PM ET
    $HWKN
    Specialty Chemicals
    Consumer Discretionary

    $HWKN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Faulconbridge James A bought $388,860 worth of shares (3,000 units at $129.62), increasing direct ownership by 6% to 52,407 units (SEC Form 4)

    4 - HAWKINS INC (0000046250) (Issuer)

    2/6/26 4:12:03 PM ET
    $HWKN
    Specialty Chemicals
    Consumer Discretionary

    VICE PRESIDENT OF OPERATIONS Grahek Drew M. bought $200,506 worth of shares (1,587 units at $126.34), increasing direct ownership by 4% to 39,640 units (SEC Form 4)

    4 - HAWKINS INC (0000046250) (Issuer)

    11/5/25 4:31:01 PM ET
    $HWKN
    Specialty Chemicals
    Consumer Discretionary

    Director Faulconbridge James A bought $161,899 worth of shares (1,800 units at $89.94), increasing direct ownership by 4% to 47,817 units (SEC Form 4)

    4 - HAWKINS INC (0000046250) (Issuer)

    6/14/24 4:09:43 PM ET
    $HWKN
    Specialty Chemicals
    Consumer Discretionary

    $HWKN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James initiated coverage on Hawkins

    Raymond James initiated coverage of Hawkins with a rating of Mkt Perform

    7/24/25 7:27:35 AM ET
    $HWKN
    Specialty Chemicals
    Consumer Discretionary

    Hawkins upgraded by BWS Financial with a new price target

    BWS Financial upgraded Hawkins from Neutral to Buy and set a new price target of $160.00

    4/14/25 9:28:56 AM ET
    $HWKN
    Specialty Chemicals
    Consumer Discretionary

    CJS Securities initiated coverage on Hawkins with a new price target

    CJS Securities initiated coverage of Hawkins with a rating of Market Outperform and set a new price target of $125.00

    4/1/25 9:13:14 AM ET
    $HWKN
    Specialty Chemicals
    Consumer Discretionary

    $HWKN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO AND PRESIDENT Hawkins Patrick H. gifted 1,040 shares and received a gift of 260 shares, decreasing direct ownership by 0.25% to 315,737 units (SEC Form 4)

    4 - HAWKINS INC (0000046250) (Issuer)

    2/25/26 4:59:20 PM ET
    $HWKN
    Specialty Chemicals
    Consumer Discretionary

    Director Faulconbridge James A bought $388,860 worth of shares (3,000 units at $129.62), increasing direct ownership by 6% to 52,407 units (SEC Form 4)

    4 - HAWKINS INC (0000046250) (Issuer)

    2/6/26 4:12:03 PM ET
    $HWKN
    Specialty Chemicals
    Consumer Discretionary

    VICE PRESIDENT OF OPERATIONS Grahek Drew M. gifted 1,460 shares, decreasing direct ownership by 4% to 38,184 units (SEC Form 4)

    4 - HAWKINS INC (0000046250) (Issuer)

    12/11/25 4:15:20 PM ET
    $HWKN
    Specialty Chemicals
    Consumer Discretionary

    $HWKN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hawkins Inc.

    SC 13G/A - HAWKINS INC (0000046250) (Subject)

    10/31/24 11:54:59 AM ET
    $HWKN
    Specialty Chemicals
    Consumer Discretionary

    SEC Form SC 13G/A filed by Hawkins Inc. (Amendment)

    SC 13G/A - HAWKINS INC (0000046250) (Subject)

    2/13/24 5:06:13 PM ET
    $HWKN
    Specialty Chemicals
    Consumer Discretionary

    SEC Form SC 13G/A filed by Hawkins Inc. (Amendment)

    SC 13G/A - HAWKINS INC (0000046250) (Subject)

    2/9/24 9:59:13 AM ET
    $HWKN
    Specialty Chemicals
    Consumer Discretionary

    $HWKN
    Leadership Updates

    Live Leadership Updates

    View All

    THE TRŪ® SHRIMP COMPANIES APPOINTS HAWKINS AS EXCLUSIVE U.S. DISTRIBUTOR FOR TRŪ® CHITOSAN

    BALATON, Minn., Aug. 16, 2023 /PRNewswire/ -- The trū® Shrimp Companies, Inc. ("trū Shrimp") announced today that trū Shrimp has appointed Hawkins, Inc. ("Hawkins") (NASDAQ:HWKN) as the exclusive distributor of its trū® Chitosan products into the United States' pharmaceutical and medical device industries. trū Chitosan is derived from the exoskeletons of trū Shrimp's production of consumer shrimp. Chitosan is a molecule refined from the shell of shrimp and is used for numerous pharmaceutical and medical applications. trū Shrimp is the only United States producer of chitosan that meets the strict medical specifications of the United States Pharmacopoeia – National Formulary (USP-NF) monograph

    8/16/23 9:00:00 AM ET
    $HWKN
    Specialty Chemicals
    Consumer Discretionary

    Hawkins, Inc.  Announces Retirement of Director John McKeon

    Minneapolis, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Hawkins, Inc. (Nasdaq: HWKN) today announced that John S. McKeon has notified us of his retirement from our Board of Directors and its committees effective as of December 31, 2020.  Mr. McKeon has been a member of the Board since 1984 and has served as Chair of the Board since 2005. “We will miss Jack on the Board and appreciate his many years of dedicated service to Hawkins,” said Patrick H. Hawkins, Chief Executive Officer and President. “Over the 36 years that Jack has served on the Board, we have seen Hawkins grow tremendously in both size and scope.  With his support and guidance, we have built a solid company that is poised for cont

    12/18/20 4:10:00 PM ET
    $HWKN
    Specialty Chemicals
    Consumer Discretionary

    $HWKN
    Financials

    Live finance-specific insights

    View All

    Hawkins, Inc. Reports Third Quarter Fiscal 2026 Results

    ROSEVILLE, Minn., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Hawkins, Inc. (NASDAQ:HWKN) today announced results for the three and nine months ended December 28, 2025, its third quarter of fiscal 2026. Third Quarter Fiscal Year 2026 Highlights: Record third quarter results for revenue, gross profit, operating income, and adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("adjusted EBITDA"), a non-GAAP measure.Revenue growth of 8% over the same period of the prior year, including Water Treatment segment growth of 21% and Industrial Solutions segment growth of 10%.Gross profit increased 5% over the same period of the prior year.Diluted earnings per share ("EPS") of $0.69 decre

    1/28/26 4:10:00 PM ET
    $HWKN
    Specialty Chemicals
    Consumer Discretionary

    Hawkins, Inc. Declares Quarterly Cash Dividend of $0.19 Per Share

                                                                     ROSEVILLE, Minn., Jan. 28, 2026 (GLOBE NEWSWIRE) -- At its recent board meeting, the Board of Directors of Hawkins, Inc. (NASDAQ:HWKN) declared a quarterly cash dividend of $0.19 per share, payable February 27, 2026, to shareholders of record at the close of business on February 13, 2026. Hawkins has consistently paid out a dividend since 1985. About Hawkins, Inc. Hawkins, Inc. was founded in 1938 and is a leading water treatment and specialty ingredients company that formulates, manufactures, distributes and blends products for its Water Treatment, Food & Health Sciences and Industrial Solutions customers. Headquartered

    1/28/26 4:05:00 PM ET
    $HWKN
    Specialty Chemicals
    Consumer Discretionary

    HAWKINS, INC. TO RELEASE THIRD QUARTER FISCAL 2026 FINANCIAL RESULTS ON JANUARY 28, 2026

    ROSEVILLE, MINN., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Hawkins, Inc. (NASDAQ:HWKN) announced today that it expects to release its financial results for its fiscal 2026 third quarter ended December 28, 2025 after the market closes on January 28, 2026 at approximately 4:10 p.m. Eastern Time.  About Hawkins, Inc. Hawkins, Inc. was founded in 1938 and is a leading water treatment and specialty ingredients company that formulates, manufactures, distributes, and blends products for its Water Treatment, Food & Health Sciences and Industrial Solutions customers. Headquartered in Roseville, Minnesota, the Company has 65 facilities in 28 states and creates value for its customers through superb cust

    1/14/26 8:30:00 AM ET
    $HWKN
    Specialty Chemicals
    Consumer Discretionary